Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?

BACKGROUND: Despite the revolutionary success of introducing tyrosine kinase inhibitors (TKIs), such as imatinib mesylate (IM), for treating chronic myeloid leukemia (CML), a substantial proportion of patients’ treatments fail. AIM: This study investigates the correlation between patient adherence a...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Dewik, Nader I., Morsi, Hisham M., Samara, Muthanna M., Ghasoub, Rola S., Gnanam, Cinquea C., Bhaskaran, Subi K., Nashwan, Abdulqadir J., Al-Jurf, Rana M., Ismail, Mohamed A., AlSharshani, Mohammed M., AlSayab, Ali A., Ben-Omran, Tawfeg I., Khatib, Rani B., Yassin, Mohamed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047706/
https://www.ncbi.nlm.nih.gov/pubmed/27721664
http://dx.doi.org/10.4137/CMO.S32822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047706/
https://www.ncbi.nlm.nih.gov/pubmed/27721664
http://dx.doi.org/10.4137/CMO.S32822

Ejemplares similares